SCHEMBL1242563

SCHEMBL1242563

Brc1ccc(NCc2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 1/20 0.66
HTT P42858 1/20 0.64
NPC1 O15118 2/20 0.59
MEN1 O00255 2/20 0.59
GAA P10253 2/20 0.59
MAPT P10636 2/20 0.59
KMT2A Q03164 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
RAB9A P51151 1/20 0.59
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
ALDH1A1 P00352 2/20 0.55
CA12 O43570 1/20 0.55
CA9 Q16790 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2D6 P10635 1/20 0.55
FFAR1 O14842 1/20 0.53
FFAR4 Q5NUL3 1/20 0.53
PTPN1 P18031 1/20 0.53
PTPRZ1 P23471 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3181376 0.91 AGER (0.66) AGERHTTNPC1MEN1GAA
SCHEMBL1924100 0.89 HTT (0.78) HTTMEN1GAAMAPTKMT2A
SCHEMBL11510347 0.88 FFAR1 (0.63) AGERHTTNPC1MEN1GAA
SCHEMBL19534133 0.84 FFAR1 (0.61) AGERHTTNPC1MEN1GAA
SCHEMBL22628164 0.84 HTT (0.71) HTTMEN1KMT2AL3MBTL1CA1
N-Benzylaniline SCHEMBL7840 0.84 HTT (0.71) HTTMEN1KMT2AL3MBTL1CA1
SCHEMBL10756655 0.82 HTT (0.69) HTTMEN1KMT2ACA1CA2
N-Benzylaniline SCHEMBL357137 0.81 HTT (0.68) HTTMEN1KMT2AL3MBTL1CA1
N-Benzylaniline SCHEMBL3602124 0.81 HTT (0.68) HTTMEN1MAPTKMT2AL3MBTL1
N-Benzylaniline SCHEMBL2176624 0.81 HTT (0.68) HTTMEN1KMT2AL3MBTL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110963927-A Allylation method of N-benzyl aniline compound 重庆大学 2020-04-07 CN claimed
CN-107129442-A A kind of α Process for the cyanation of monoalkyl substituted aniline 重庆大学 2017-09-05 CN claimed
CN-119701982-A Application of niobium oxide supported copper catalyst in synthesis of secondary amine or derivative thereof from aromatic nitro compound and benzyl alcohol compound 兰州大学 2025-03-28 CN disclosed
CN-116102430-B Alkylation synthesis method for in-situ catalytic alcohols 中山大学 2025-03-14 CN disclosed
CN-115745808-B Method for preparing secondary amine compound by catalyzing reduction of imine compound 延安大学 2024-04-30 CN disclosed
CN-116102430-A Alkylation synthesis method for in-situ catalytic alcohols 中山大学 2023-05-12 CN disclosed
CN-112409188-B Method for synthesizing N-alkylamine 南京理工大学 2023-05-05 CN disclosed
CN-114805093-B Preparation method of diarylamines 暨南大学 2023-04-25 CN disclosed
CN-111807971-B Alkylation synthesis method for in-situ catalysis of alcohols 中山大学 2023-03-24 CN disclosed
CN-115745808-A Method for preparing secondary amine compound by catalyzing reduction of imine compound 延安大学 2023-03-07 CN disclosed
WO-2023016562-A1 POLYCYCLIC COMPOUND AND USE THEREOF 浙江同源康医药股份有限公司 2023-02-16 WO disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed
US-20080146572-A1 N-SULFONYLUREA APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2008-06-19 US disclosed
US-7358251-B2 N-sulfonylurea apoptosis promoters ABBOTT LABORATORIES (US) 2008-04-15 US disclosed
EP-1487811-B1 N-SULFONYLUREA APOPTOSIS PROMOTERS ABBOTT LAB (US) 2007-09-05 EP disclosed
US-7030115-B2 N-sulfonylurea apoptosis promoters ABBOTT LABORATORIES (US) 2006-04-18 US disclosed
US-20060074085-A1 N-sulfonylurea apoptosis promoters ABBVIE INC. 2006-04-06 US disclosed
EP-1487811-A1 N-SULFONYLUREA APOPTOSIS PROMOTERS Abbott Laboratories (US) 2004-12-22 EP disclosed
US-20030236247-A1 N-sulfonylurea apoptosis promoters ABBVIE INC. 2003-12-25 US disclosed
WO-2003080586-A1 N-SULFONYLUREA APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2003-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 AGER 3548/4885HTT 2165/4885NPC1 1483/4885
US-20080146572-A1 N-SULFONYLUREA APOPTOSIS PROMOTERS BAX, BCL2, BAD AGER 1362/4885HTT 2091/4885NPC1 1851/4885
US-20060074085-A1 N-sulfonylurea apoptosis promoters BAX, BCL2, BAD AGER 1362/4885HTT 2091/4885NPC1 1851/4885
US-20030236247-A1 N-sulfonylurea apoptosis promoters BAX, BCL2, AIFM1 AGER 1796/4885HTT 2698/4885NPC1 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.